ResearchA curated selection of insights from the Maven Bio team.
Four Q3 2026 CBER approvals span metabolic disease, melanoma, influenza prevention and transfusion, up from two in Q2 on the same patient-use boundary.
Two Phase 3 CLDN18.2 ADC readouts at ESMO 2026: arcotatug and sonesitatug endpoint results, trial populations and later-line gastric cancer competition.
At WCLC 2026, two Phase 3 B7-H3 ADCs each reduced the risk of death by 54% versus topotecan in relapsed SCLC; MAVERICK improved cognitive outcomes.
Eight Q3 2026 Nasdaq drug-developer IPOs raised $2.284 billion, below Q2's $2.83 billion but eight times Q3 2025, across a broad therapeutic-area spread.
How revenue mix changed at J&J, Roche, AstraZeneca and Novo Nordisk from 2019 to 2024, with a separate 2013–2023 comparison of leading product lines.
An analysis of the current clinical-stage landscape for KRAS-targeted therapies, examining the divergence between KRAS G12D–selective programs and pan-KRAS approaches, development maturity, and emerging tumor-specific strategies in pancreatic cancer.
A research report analyzing the launch velocity of new molecular entities (NMEs) and biologic entities (NBEs) across major pharmaceutical companies from 2021 to 2025.
In 2025, the FDA approved 46 new drugs across oncology, immunology, neurology, and rare diseases. This report examines key approval trends, mechanisms, and therapeutic focus areas shaping biopharma strategy.
An analysis of the largest pharma and biotech M&A deals of 2025, examining how Big Pharma deployed capital toward late-stage assets, platform technologies, and durable therapeutic franchises amid rising development costs and approaching patent expiries.
